What Insilico Medicine does
Insilico Medicine is an AI drug discovery company whose Pharma.ai suite applies generative AI to drug discovery, scientific research and longevity work. It is aimed at pharmaceutical and biotech R&D teams, researchers and licensing partners. The suite includes PandaOmics for target discovery and prioritisation, Chemistry42 for generative chemistry with modules for ADMET, molecular dynamics and retrosynthesis, Generative Biologics for biomolecule design, and inClinico for clinical trial design and prediction. The site also names Science42: DORA, a multi-agent research assistant, the Nach01 multimodal foundation model, PreciousGPT longevity models, MCP servers and an automated lab environment. Insilico also runs its own therapeutic pipeline. Pricing is not published; visitors contact the company about Pharma.ai.
How Insilico Medicine compares with its closest alternatives
2 of the 5 closest alternatives have a free plan; Insilico Medicine does not. All 5 offer an API, as Insilico Medicine does. Insilico Medicine offers a web app. Of the alternatives, all 5 offer a web app. Insilico Medicine was founded in 2014; the alternatives were founded between 2011 and 2021, 2 of them earlier. Insilico Medicine is based in Hong Kong; none of the 2 alternatives with a known headquarters is in Hong Kong. They are in the United Kingdom and the United States.